GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Faron Pharmaceuticals Oy (FRA:4FR) » Definitions » 3-Year ROIIC %

Faron Pharmaceuticals Oy (FRA:4FR) 3-Year ROIIC % : -636.90% (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Faron Pharmaceuticals Oy 3-Year ROIIC %?

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. Faron Pharmaceuticals Oy's 3-Year ROIIC % for the quarter that ended in Dec. 2023 was -636.90%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Faron Pharmaceuticals Oy's 3-Year ROIIC % or its related term are showing as below:

FRA:4FR's 3-Year ROIIC % is ranked worse than
89.91% of 1358 companies
in the Biotechnology industry
Industry Median: -13.43 vs FRA:4FR: -636.90

Faron Pharmaceuticals Oy 3-Year ROIIC % Historical Data

The historical data trend for Faron Pharmaceuticals Oy's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Faron Pharmaceuticals Oy 3-Year ROIIC % Chart

Faron Pharmaceuticals Oy Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
3-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,124.89 -269.17 -13.45 -511.90 -636.90

Faron Pharmaceuticals Oy Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
3-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -511.90 - -636.90 -

Competitive Comparison of Faron Pharmaceuticals Oy's 3-Year ROIIC %

For the Biotechnology subindustry, Faron Pharmaceuticals Oy's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Faron Pharmaceuticals Oy's 3-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Faron Pharmaceuticals Oy's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Faron Pharmaceuticals Oy's 3-Year ROIIC % falls into.



Faron Pharmaceuticals Oy 3-Year ROIIC % Calculation

Faron Pharmaceuticals Oy's 3-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

3-Year ROIIC %=3-Year Incremental Net Operating Profit After Taxes (NOPAT)**/3-Year Incremental Invested Capital**
=( -28.567 (Dec. 2023) - -16.6639924 (Dec. 2020) )/( 7.393 (Dec. 2023) - 5.384 (Dec. 2020) )
=-11.9030076/2.009
=-592.48%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Faron Pharmaceuticals Oy  (FRA:4FR) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Faron Pharmaceuticals Oy 3-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Faron Pharmaceuticals Oy's 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Faron Pharmaceuticals Oy Business Description

Traded in Other Exchanges
Address
Joukahaisenkatu 6 B, Turku, FIN, 20520
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested for the prevention of complications that arise from cytokine release syndrome, or hyperinflammatory conditions.

Faron Pharmaceuticals Oy Headlines

No Headlines